<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03641768</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00100030</org_study_id>
    <nct_id>NCT03641768</nct_id>
  </id_info>
  <brief_title>Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics</brief_title>
  <official_title>Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about how trauma, posttraumatic stress disorder (PTSD),
      and mild traumatic brain injury that can occur during deployment affect the brain. The
      investigators also want to learn how PTSD and mild traumatic brain injury can affect the
      chance of developing Alzheimer disease later in life. The investigators will study this by
      using magnetic resonance imaging and positron emission tomography scans to obtain pictures of
      the brain.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding not received
  </why_stopped>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortical thickness as measured by MRI scans</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta amyloid plaques as measured by PET scans</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tau proteins as measured by PET scans</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Alzheimer Dementia</condition>
  <condition>Posttraumatic Stress Disorder</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers with no trauma history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trauma only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers that do not have PTSD but have had similar trauma to those with PTSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTSD only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers with PTSD but no traumatic brain injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTSD and TBI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers with PTSD and mild traumatic brain injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>PTSD and TBI</arm_group_label>
    <arm_group_label>PTSD only</arm_group_label>
    <arm_group_label>Trauma only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET</intervention_name>
    <description>You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>PTSD and TBI</arm_group_label>
    <arm_group_label>PTSD only</arm_group_label>
    <arm_group_label>Trauma only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>18F-Florbetapir</intervention_name>
    <description>At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>PTSD and TBI</arm_group_label>
    <arm_group_label>PTSD only</arm_group_label>
    <arm_group_label>Trauma only</arm_group_label>
    <other_name>PET tracer for Amyloid-beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radioligand 18F-AV-1451</intervention_name>
    <description>At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>PTSD and TBI</arm_group_label>
    <arm_group_label>PTSD only</arm_group_label>
    <arm_group_label>Trauma only</arm_group_label>
    <other_name>PET tracer for Tau protein</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65

          -  Previously enrolled in studies of OEF/OIF veterans by the same investigators

          -  Free of implanted metal objects or mental shards in eyes

          -  Fluent in English and capable of consenting

        Exclusion Criteria:

          -  Axis I disorders other than Major Depressive Disorder or PTSD

          -  Current substance abuse or lifetime substance dependence (other than nicotine)

          -  High risk for suicide

          -  Claustrophobia

          -  Neurological disorders

          -  Learning disability or developmental delay

          -  Major medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajendra Morey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VA</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer Dementia</keyword>
  <keyword>PTSD</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

